Latigo Biotherapeutics
United States · Biotech · Healthtech
Latigo Biotherapeutics develops non-opioid pain medicines that target peripheral pain signaling.
Product
Latigo develops investigational small-molecule medicines for acute and chronic pain. Its clinical programs target Nav1.8, a sodium channel involved in pain signaling, as an alternative mechanism to opioid-based treatment.
The company’s pipeline includes LTG-001 for acute pain and LTG-305 for chronic pain. Its development work spans clinical studies of these candidates and research on a broader portfolio of non-opioid therapies.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $150M | Blue Owl Capital — Lead5AM Ventures — ParticipantAccess Biotechnology — ParticipantAlexandria Venture Investments — ParticipantCormorant Asset Management — ParticipantDeep Track Capital — ParticipantForesite Capital — ParticipantKern Capital — ParticipantQatar Investment Authority (QIA) — ParticipantRock Springs Capital — ParticipantSanofi Ventures — ParticipantUPMC Enterprises — ParticipantWestlake BioPartners — Participant |